One platform for all researcher needs
AI-powered academic writing assistant
Your #1 AI companion for literature search
AI tool for graphics, illustrations, and artwork
Unlock unlimited use of all AI tools with the Editage All Access membership.
Explore Editage All Accesshttps://doi.org/10.1182/blood-2018-99-119944
Copy DOI Journal: Blood |  Publication Date: Nov 29, 2018 |
 Citations: 20 |
Affiliation: Memorial Sloan Kettering Cancer Center, Stanford University, Stanford Medicine, Portola Pharmaceuticals (United States), University of Michigan–Ann Arbor, University of Chicago, University of Washington, Seattle Cancer Care Alliance, The University of Texas MD Anderson Cancer Center, Hackensack University Medical Center, Sarah Cannon, Hollings Cancer Center, Palmetto Hematology Oncology, Medical University of South CarolinaThe Novel SYK/JAK Inhibitor Cerdulatinib Demonstrates Good Tolerability and Clinical Response in a Phase 2a Study in Relapsed/Refractory Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma
Sign-in/Register to access full text options 
Free) Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
